@Article{,
AUTHOR = {Jacqueline Zillioux, Matthew DiLizia, Basil Schaheen, Rudolph Rustin, Tracey L. Krupski},
TITLE = {Ileal perforation in the setting of atezolizumab immunotherapy for advanced bladder cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {25},
YEAR = {2018},
NUMBER = {5},
PAGES = {9525--9526},
URL = {http://www.techscience.com/CJU/v25n5/60742},
ISSN = {1488-5581},
ABSTRACT = {Atezolizumab is a promising immunotherapy for 
advanced urothelial carcinoma. Like other immune 
checkpoint inhibitors, it can produce rare immune-related 
adverse events (IRAEs). Here we present the recent case 
of a patient with metastatic bladder cancer who developed 
diarrhea and abdominal pain months after beginning atezolizumab therapy. He presented to our institution 
with an ileal perforation secondary to atezolizumabinduced enterocolitis. After surgical repair, the patient’s 
condition improved, and he was discharged. We discuss 
the management of atezolizumab-induced enterocolitis, 
including the importance of early recognition and 
intervention to prevent more devastating complications.},
DOI = {}
}